Medicalgorithmics’ innovative project “Kardiobeat.CT” has been selected by the Polish Agency for Enterprise Development (PARP) for co-financing in the amount of PLN 9.4 million under the SMART Pathway initiative. The aim of this pioneering endeavor by the Polish medtech company is to develop an advanced diagnostic tool for the automatic detection and assessment of atherosclerotic plaques – a solution currently unavailable on the market. The new project will leverage the capabilities of the already commercialized, CE-certified VCAST platform. Funding disbursement for the project, with a total value of PLN 19 million, will commence following the execution of the agreement between Medicalgorithmics and PARP.
This technology grant is a strong endorsement of our innovation and a major step forward in executing our long-term strategy of developing advanced medical imaging solutions. The support from FENG funds will also allow us to accelerate the development of new applications for our CE-certified VCAST platform and enhance our impact on improving cardiovascular diagnostics” commented Dr. Kris Siemionow, CEO of Medicalgorithmics.
Medicalgorithmics has already successfully introduced groundbreaking solutions to the market, including the DRAI software and DRP platform, both featured in Nature Medicine. The company is also dynamically expanding its proprietary, AI-powered cardiac imaging technology – VCAST – which aids clinicians in diagnosing coronary artery disease. This solution offers a fast, non-invasive, and cost-effective alternative to conventional, highly invasive procedures such as coronary angiography.
In mid-October of last year, Medicalgorithmics completed CE certification for the VCAST software. Additionally, on July 11th this year, the company’s subsidiary – Kardiolytics – was granted a European patent for its method of numerical modeling of blood flow in arteries. This innovation, already protected by a U.S. patent since April 2024, represents a critical component of the company’s cutting-edge technology. The Kardiobeat.CT project will build on the capabilities of the commercialized VCAST platform and expand the functionality of Medicalgorithmics’ unique medtech solution.
“The AI algorithms and cloud-based software developed under this project will utilize cardiac CT data to enable physicians to more accurately assess the risk associated with the presence of atherosclerotic plaque. Factors such as plaque type, volume, location, and other morphological features directly impact patient risk. With this funding, we will be able to develop and implement new software for plaque analysis – a tool highly needed in daily clinical practice,” added Przemysław Tadla, CTO of Medicalgorithmics.
The year 2025 has brought a significant increase in interest in the company’s solutions and a notable acceleration in acquiring new customers. Since the beginning of the year, Medicalgorithmics has signed 13 new partnership agreements with entities from the United States, Canada, Australia, South Korea, Turkey, and various European countries – matching the total number of deals signed throughout all of 2024. At the same time, the company has recorded a substantial year-over-year increase in the number of ECG studies performed. In Q1 2025 alone, the volume reached 92,000 tests, reflecting an almost 100% year-over-year growth.